Fragment-based drug design

Innovations in Pharmaceutical Technology

Volumn , Issue 25, 2008, Pages 18-22

  Bailey, David ^a   Boyd, Susan ^a   England, Paul ^a   de Esch, Iwan ^a,b  

^a IOTA Pharmaceuticals Ltd

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; G PROTEIN COUPLED RECEPTOR; HISTAMINE H4 RECEPTOR ANTAGONIST; PROTEINASE;

CHEMICAL ANALYSIS; DRUG BINDING; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FRAGMENT BASED DRUG DESIGN; HIGH THROUGHPUT SCREENING; LIGAND BINDING; METHODOLOGY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REVIEW; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

EID: 45849102759     PISSN: 14717204     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (22)

1. Lipinski C and Hopkins A, Navigating chemical space for biology and medicine. Nature 432, pp855-861, 2004
2. Jhoti H, Cleasby A, Verdonk M and Williams G, Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol. 11, pp485-493, 2007
3. Hann MM and Oprea TI, Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol. 8, pp255-63, 2004
4. Hopkins AL and Groom CR, The druggable genome. Nat Rev Drug Discov. 1, pp727-730, 2002
5. Hajduk PJ and Greer J, A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov. 6, pp211-219, 2007
6. Williams DL and Lindsley CW, Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). Curr Top Med Chem. 5, pp825-846, 2005
7. Wells JA and McClendon CL, Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 450, pp1,001-1,009.
8. Schuffenhauer A, Ruedisser S, Marzinzik AL, Jahnke W, Blommers M, Selzer P and Jacoby E, Library design for fragment based screening. Curr Top Med Chem. 5, pp751-762, 2005
9. Leach AR, Hann MM, Burrows JN and Griffen EJ, Fragment screening: An introduction. Mol Biosyst. 2, 430-46, 2006
10. Hohwy M, Spadola L, Lundquist B, Hawtin P, Dahmén J, Groth-Clausen I, Nilsson E, Persdotter S, von Wachenfeldt K, Folmer RHA and Edman K, Novel Prostaglandin D Synthase Inhibitors Generated by Fragment-Based Drug Design. J Med Chem (web release date March 15, 2008), 2008
11. Congreve M, Carr R, Murray C and Jhoti HA, A "rule of three" for fragment-based lead discovery. Drug Discovery Today, 8, pp876-877, 2003
12. Hopkins AL, Groom CR and Alex A, Ligand efficiency: A useful metric for lead selection. Drug Discov Today. 9, pp430-431, 2004
13. Shoichet BK, Virtual screening of chemical libraries. Nature. 432, pp862-865, 2004
14. Hajduk PJ, Bures M, Praestgaard J and Fesik SW, Privileged molecules for protein binding identified from NMR-based screening. J Med Chem. 43, pp3,443-3,447, 2000
15. Smits R, Lim H, Hanzer A, Zuiderveld O, Guaita E, Adami M, Coruzzi G, Leurs, R and de Esch I, Fragment-based design of new H4 receptor ligands with anti-inflammatory properties in-vivo. J Med Chem (web release date March 22, 2008), 2008
16. Zartler ER and Shapiro MJ, Protein NMR-based screening in drug discovery. Curr Pharm Des. 12, pp3,963-3,972, 2006
17. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van der Oost J, Smit AB and Sixma TK, Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411, pp269-276, 2001
18. Kobilka B and Schertler GF, New G-protein-coupled receptor crystal structures: Insights and limitations. Trends Pharmacol Sci. 29, pp79-83, 2008
19. Topiol S and Sabio M, Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Bioorg Med Chem Lett. 18, pp 1,598-1,602, 2008
20. Huber W, A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions. J Mol Recognit. 18, pp273-281, 2005
21. Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J and Zhang KY, A family of phosphodiesterase inhibitors discovered by co-crystallography and scaffold-based drug design. Nat Biotechnol. 23, pp201-207, 2005
22. Smits R, Lim H, Leurs R and de Esch I, Quinazolines and related heterocyclic compounds, and their therapeutic use. W02008003702, 2008